Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melita Kenealy

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Palliative & Supportive Care|October 10, 2019
A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patientsJoanne Brooker, John Julian, Jeremy Millar, et al.
Haematologica|December 15, 2018
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemiaMelita Kenealy, Mark Hertzberg, Warwick Benson, et al.
Leukemia & Lymphoma|February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT studyNoemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Nature Communications|May 13, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsJulie A I Thoms, Feng Yan, Henry R Hampton, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Palliative & Supportive Care|October 10, 2019
A feasibility and acceptability study of an adaptation of the Mindful Self-Compassion program for adult cancer patientsJoanne Brooker, John Julian, Jeremy Millar, et al.
Haematologica|December 15, 2018
Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemiaMelita Kenealy, Mark Hertzberg, Warwick Benson, et al.
Leukemia & Lymphoma|February 20, 2019
Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT studyNoemi Horvath, Andrew Spencer, Melita Kenealy, et al.
Nature Communications|May 13, 2025
Clinical response to azacitidine in MDS is associated with distinct DNA methylation changes in HSPCsJulie A I Thoms, Feng Yan, Henry R Hampton, et al.
Pageof 2